NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to analysts' expectations of $21.60 million. View Amyris' Earnings History.

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

Amyris issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

2 equities research analysts have issued 12-month price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' stock price to reach $9.50 in the next year. This suggests a possible upside of 219.9% from the stock's current price. View Analyst Price Targets for Amyris.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

News headlines about AMRS stock have been trending neutral on Sunday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amyris earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Amyris.

Amyris saw a increase in short interest in December. As of December 31st, there was short interest totalling 17,190,000 shares, an increase of 11.7% from the December 15th total of 15,390,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is currently 16.5 days. Approximately 31.4% of the shares of the stock are short sold. View Amyris' Current Options Chain.

Some companies that are related to Amyris include Phillips 66 (PSX), Valero Energy (VLO), Marathon Petroleum (MPC), HollyFrontier (HFC), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Delek US (DK), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), Green Plains (GPRE), REX American Resources (REX), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Intel (INTC), Novavax (NVAX), General Electric (GE), Inovio Pharmaceuticals (INO) and Amarin (AMRN).

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $2.97.

Amyris has a market capitalization of $313.34 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]